Astonea Labs has received a certificate from the Supreme Board of Drugs and Medical Appliances (SBDMA), Ministry of Health and Population, Republic of Yemen, confirming the successful inspection of its manufacturing facility. The inspection was conducted at the company's plant located in Village Haripur, Tehsil Raipur Rani, Panchkula, Haryana. The receipt of the certificate on July 14, 2026, validates the facility's compliance with the standards required by the Yemeni regulatory authority.

The intimation was submitted to BSE Limited pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure confirms that the inspection process has been formally concluded with a positive outcome.

Inspection Details

The regulatory audit focused on the manufacturing capabilities and quality standards of the facility situated in Haryana. The successful completion and subsequent certification allow the company to maintain its operational alignment with the requirements of the SBDMA.

Astonea Labs Ltd reported a 15.6% decline in net profit to ₹451.52 lakh for the financial year ended March 31, 2026, despite a 51.3% increase in revenue from operations to ₹14,758.44 lakh. The company’s total income for the year stood at ₹14,810.43 lakh, compared to ₹9,770.77 lakh in the previous year. The board approved the standalone financial results on May 30, 2026, authorizing Director Pardeep Dalal to sign the documents.

The statutory auditor, Avnish Sharma & Associates, issued an unmodified opinion on the results but noted that internal financial controls over financial reporting were operating ineffectively as of March 31, 2026. The report stated the company is in the process of strengthening these controls. Additionally, the auditor highlighted a major fire incident on April 27, 2026, at the company's factory premises, which caused substantial damage to the building, plant, machinery, and stocks. The management estimated a loss of ₹9.39 crore, though the insurance claim is yet to be filed.

Financial Performance

Revenue growth was driven by operational expansion, though profitability was impacted by rising costs. Total expenses for the year increased to ₹14,248.28 lakh from ₹9,063.66 lakh in the prior year. The cost of materials consumed rose to ₹10,278.62 lakh, while employee benefit expenses increased to ₹762.76 lakh. Finance costs decreased to ₹326.28 lakh from ₹365.61 lakh in the previous year.

Key Disclosures and Utilization of Funds

The company incorporated a wholly-owned foreign subsidiary, Astonea LLC, in the United States on January 25, 2026, but has not yet subscribed to any capital or commenced business operations. Astonea Labs also entered into a sales agreement with associate concern Astonea One Private Limited, generating sales of ₹41.41 crore and paying commissions of ₹15.43 crore.

Proceeds from the Initial Public Offer, totaling ₹37.67 crore, were utilized primarily for working capital and general corporate purposes. The board approved a variation in the utilization of IPO proceeds on February 27, 2026, which was subsequently ratified by shareholders. An investment of ₹6.25 crore was made in Damaira Pharmaceuticals Private Limited, acquiring a 25.74% equity stake. Unutilized IPO proceeds of ₹1.75 crore were maintained in a current account as of March 31, 2026.